Relmada Therapeutics (RLMD) shares continued falling on Thursday after some analysts downgraded its stock following failure in late-stage trial of anti-depressant candidate.
Mizuho downgraded the stock to neutral from outperform and slashed its price target to $1 from $23, while Leerink Partners lowered its rating to market perform from outperform, also with a $1 price target.
Relmada on Wednesday said that an independent data monitoring committee has determined that a late-stage study of REL-1017 as an adjunctive treatment for major depressive disorder is "futile." The company will determine its next steps after assessing the full dataset.
The company's stock was down nearly 16% in recent trading after falling more than 70% on Wednesday.
Price: 0.53, Change: -0.10, Percent Change: -15.71
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。